Mount Yale Investment Advisors LLC boosted its stake in shares of Pfizer Inc. (NYSE:PFE) by 58.4% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 51,007 shares of the biopharmaceutical company’s stock after purchasing an additional 18,796 shares during the period. Mount Yale Investment Advisors LLC’s holdings in Pfizer were worth $1,851,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Naples Global Advisors LLC lifted its position in shares of Pfizer by 5.4% in the second quarter. Naples Global Advisors LLC now owns 33,695 shares of the biopharmaceutical company’s stock valued at $1,222,000 after acquiring an additional 1,712 shares in the last quarter. Steward Partners Investment Advisory LLC lifted its position in shares of Pfizer by 25.1% in the second quarter. Steward Partners Investment Advisory LLC now owns 285,325 shares of the biopharmaceutical company’s stock valued at $10,352,000 after acquiring an additional 57,176 shares in the last quarter. Destination Wealth Management lifted its position in shares of Pfizer by 962,667.3% in the second quarter. Destination Wealth Management now owns 500,639 shares of the biopharmaceutical company’s stock valued at $18,163,000 after acquiring an additional 500,587 shares in the last quarter. Sterling Capital Management LLC lifted its position in shares of Pfizer by 16.6% in the second quarter. Sterling Capital Management LLC now owns 2,478,848 shares of the biopharmaceutical company’s stock valued at $89,933,000 after acquiring an additional 353,212 shares in the last quarter. Finally, Pennsylvania Trust Co lifted its position in shares of Pfizer by 10.9% in the second quarter. Pennsylvania Trust Co now owns 681,255 shares of the biopharmaceutical company’s stock valued at $28,127,000 after acquiring an additional 67,151 shares in the last quarter. Institutional investors own 69.42% of the company’s stock.
NYSE:PFE opened at $43.92 on Friday. The company has a current ratio of 1.43, a quick ratio of 1.15 and a debt-to-equity ratio of 0.47. The stock has a market capitalization of $268.71 billion, a P/E ratio of 16.57, a PEG ratio of 2.25 and a beta of 0.88. Pfizer Inc. has a 12 month low of $33.20 and a 12 month high of $46.47.
Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 30th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.75 by $0.03. The company had revenue of $13.30 billion for the quarter, compared to the consensus estimate of $13.53 billion. Pfizer had a return on equity of 25.26% and a net margin of 44.63%. The firm’s revenue for the quarter was up 1.0% on a year-over-year basis. During the same period in the previous year, the business earned $0.67 earnings per share. On average, equities research analysts anticipate that Pfizer Inc. will post 3 EPS for the current year.
The company also recently announced a quarterly dividend, which was paid on Monday, December 3rd. Investors of record on Friday, November 9th were given a $0.34 dividend. The ex-dividend date of this dividend was Thursday, November 8th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.10%. Pfizer’s dividend payout ratio is currently 51.32%.
In related news, major shareholder Pfizer Inc acquired 55,556 shares of Pfizer stock in a transaction on Monday, October 15th. The shares were bought at an average cost of $18.00 per share, with a total value of $1,000,008.00. Following the completion of the purchase, the insider now directly owns 21,976,484 shares of the company’s stock, valued at approximately $395,576,712. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.06% of the stock is currently owned by insiders.
Several equities analysts have recently commented on the company. Credit Suisse Group set a $42.00 price objective on Pfizer and gave the company a “hold” rating in a research report on Monday, November 26th. JPMorgan Chase & Co. restated a “buy” rating and issued a $42.00 price objective on shares of Pfizer in a research report on Thursday, August 23rd. Atlantic Securities restated a “buy” rating and issued a $54.00 price objective on shares of Pfizer in a research report on Tuesday, November 27th. Societe Generale set a $43.00 price objective on Pfizer and gave the company a “hold” rating in a research report on Thursday, November 1st. Finally, Cantor Fitzgerald restated a “buy” rating and issued a $53.00 price objective on shares of Pfizer in a research report on Monday, November 19th. Two research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and nine have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $43.27.
WARNING: “Mount Yale Investment Advisors LLC Has $1.85 Million Position in Pfizer Inc. (PFE)” was published by American Banking News and is the sole property of of American Banking News. If you are reading this article on another publication, it was stolen and reposted in violation of United States & international copyright laws. The correct version of this article can be viewed at https://www.americanbankingnews.com/2018/12/08/mount-yale-investment-advisors-llc-has-1-85-million-position-in-pfizer-inc-pfe.html.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Recommended Story: Outstanding Shares and The Effect on Share Price
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.